Open Source Securities' investment strategy for the pharmaceutical industry in 2025: The long-term industry trend has not changed, focusing on the sector stabilizing and rebounding.

At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, and the continuous improvement of enterprise innovation capabilities are long-term industry trends that have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance income suppressing the pharmaceutical sector will gradually improve.

Zhitong FinanceNov 18 02:04 ET

Hong Kong stock market anomaly | CRO concept stocks have a leading increase, institutions believe that the future performance recovery is worth looking forward to. The demand for cost reduction in research and development of innovative drugs listed in the

CRO concept stocks are among the top gainers. As of the time of publication, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.

Zhitong FinanceNov 11 21:38 ET

[Brokerage Focus] Bocom Intl believes that the prospects of domestic CXO overseas business are mixed after Trump's election.

Golden Harvest Financial News | Bocom Intl research reports indicate that the prospects for domestic CXO overseas business after Trump's election are both positive and negative: 1) A Republican-controlled Congress may advocate 'America first' in the pharmaceutical supply chain; 2) The IRA signed by the Biden administration has an uncertain future under the Trump administration; 3) Trump may give more management responsibilities to Robert Kennedy Jr. in the medical health field, who opposes vaccines and claims to make significant reforms to the American medical healthcare system, which may bring certain pressure to downstream customers of CXO; 4) Trump's tariff policy and overall loose fiscal policy stance could lead to subsequent inflation.

Golden Finance NewsNov 10 20:04 ET

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

PR NewswireNov 7 22:27 ET

An Intrinsic Calculation For WuXi XDC Cayman Inc. (HKG:2268) Suggests It's 33% Undervalued

Simply Wall StNov 7 20:49 ET

[Brokerage Focus] Guosen Securities maintains a 'outperform the market' rating on Wuxi XDC (02268), expecting the company's business to maintain rapid growth over the next 3 years.

Guosen Securities research report pointed out that Wuxi XDC (02268) is a global leader in Antibody Drug Conjugates (ADC) contract research, development, and manufacturing organization (CRDMO), providing end-to-end services for customers throughout the entire process, empowering drug production development from start to finish, with leading comprehensive capabilities. The company's three-year revenue CAGR from 2021 to 2023 is 180.4%, and the compounded annual growth rate of net income attributable to shareholders is 120.9%. The bank stated that according to Wuxi XDC's prospectus, the ADC market is expected to grow to $64.7 billion by 2030. Due to the high complexity of developing bioconjugate drugs, ADCs are

Golden Guard Financial NewsNov 6 23:24 ET